港股異動 | 澳優(1717.HK)低位反彈近6% 終結5連跌
格隆匯12月5日丨澳優(1717.HK)終結5連跌,今日迎來反彈。現漲5.7%,報9.83港元,暫成交937萬港元,最新總市值158.6億港元。公司股價近期持續下跌,今反彈大漲。輝立證券日前報告指,澳優自家品牌配方羊奶粉保持高速增長,且啟動股份回購計劃,維持”買入”評級,目標價15.7港元。另外,澳優今年首9個月業績,收入按年增23.9%至46.8億元,若單看第三季,收入增長達28.3%。值得一提的是,8月15日,沽空機構“殺人鯨資本”發佈報告,質疑澳優誇大營業收入、隱藏成本。雖然澳優乳業一再否認殺人鯨資本的沽空,但股價仍舊低迷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.